TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The American Heart Association’s Nov. 7–9, 2026, scientific meeting is set to feature two trials of intensive blood pressure control in groups excluded from the landmark SPRINT trial: ischemic stroke survivors and higher-risk people with type 2 diabetes. Both studies tested a systolic target below 120 mmHg, but their results and implications were not included in the source report, which previews the presentations rather than reporting findings.
The American Heart Association’s 2026 scientific meeting is set to present two trials testing intensive blood pressure control in groups excluded from the landmark SPRINT study: ischemic stroke survivors and higher-risk people with type 2 diabetes. The trials, OPTIMAL-Stroke and OPTIMAL-Diabetes, each tested a systolic blood pressure target below 120 mmHg; the meeting preview did not report their results.
According to a Nov. 6 preview by MedPage Today, the two studies are scheduled among the first late-breaking presentations on Saturday, Nov. 7. Both enrolled people whose starting systolic blood pressure was between 130 and 180 mmHg and examined a target below 120 mmHg for cardiovascular protection. OPTIMAL-Stroke focused on people who had survived an ischemic stroke, while OPTIMAL-Diabetes studied higher-risk participants with type 2 diabetes.
The preview describes the studies as addressing important evidence gaps left by SPRINT, which excluded both groups. SPRINT’s findings contributed to a 2017 national redefinition of hypertension, the report said. The AHA’s main scientific sessions run from Nov. 7 through Nov. 9, with expanded programming beginning Friday, Nov. 6. The meeting is in person in Chicago, with selected sessions available by livestream.
The meeting program also includes studies of statin discontinuation, coronary procedures, cardiovascular drugs in development, pacing, atrial fibrillation, sleep apnea and AI-enabled smartwatch ECGs. Those topics are part of the wider program, but the source preview does not provide results from the scheduled presentations.
Evidence Beyond the SPRINT Population
The two trials matter because clinicians and guideline writers need evidence that applies to patients not represented in SPRINT. Stroke survivors and people with type 2 diabetes may have different risks and treatment considerations, so results from another patient population cannot automatically settle the best blood pressure target for them.
The studies test the same ambitious threshold—systolic pressure below 120 mmHg—in distinct groups. Their findings could inform discussion of intensive control in those populations, but a target alone does not establish that it is safe or beneficial for every patient in a group. The preview supplies no outcomes, adverse-event data or conclusions, so the clinical implications remain to be determined after the presentations and full reporting.
Popular right now
Hisense 43-Inch E6SR Series Hi-QLED 4K UHD Smart Roku TV (2026 Model)
Shark AV2501S AI Ultra Robot Vacuum with Self-Empty Base
De’Longhi Classic Matte Black Espresso Machine with Milk Frother
As an affiliate, we earn on qualifying purchases.
How SPRINT Left These Groups Out
SPRINT was a landmark trial of intensive blood pressure lowering, and its findings contributed to changes in how hypertension was defined nationally in 2017, MedPage Today reported. The two populations now featured in OPTIMAL-Stroke and OPTIMAL-Diabetes were excluded from SPRINT, leaving questions about whether its approach applies to them.
The AHA meeting is the setting for the initial presentations described in the report, not evidence that the questions have already been resolved. The preview identifies trial names, populations and the blood pressure target, but does not provide study methods in detail or results. It also lists other prominent meeting presentations, including trials with previously reported disappointing topline results, without supplying new findings from those sessions.
““two separate trials of intensive BP control that are expected to fill major gaps left by the landmark SPRINT trial””
— MedPage Today meeting preview by Nicole Lou
Trial Results Have Not Been Reported
The source is a meeting preview published on Nov. 6, 2026, before the scheduled Saturday presentations. It does not state whether either trial met its primary endpoint, how intensive treatment compared with its control approach, or what benefits and harms were observed. The available material also does not provide sample sizes, follow-up duration, full treatment protocols or detailed eligibility criteria.
It is therefore not possible from this report to say whether a systolic target below 120 mmHg should be adopted for stroke survivors or people with type 2 diabetes. The presentations may supply additional information, but any broader clinical conclusions would depend on the complete findings and subsequent interpretation.
Saturday Presentations Set the Next Step
OPTIMAL-Stroke and OPTIMAL-Diabetes are scheduled for Saturday, Nov. 7, during the opening late-breaking trial sessions. The meeting runs through Monday, Nov. 9, and selected sessions will be livestreamed. The next reporting milestone is the release and examination of each trial’s results, including outcome measures, safety findings and the limits of applying the findings to patients beyond those enrolled.
Until those details are available, the confirmed development is that the AHA program will put intensive blood pressure control in two SPRINT-excluded populations before the conference audience. Whether the trials change clinical guidance is not established by the preview.
Key Questions
What is the AHA development?
The 2026 AHA scientific meeting is scheduled to present two trials of intensive blood pressure control in groups excluded from SPRINT: ischemic stroke survivors and higher-risk people with type 2 diabetes.
What blood pressure target did the studies test?
Both OPTIMAL-Stroke and OPTIMAL-Diabetes tested a systolic blood pressure target below 120 mmHg for cardiovascular protection in participants whose starting systolic pressure was 130–180 mmHg, according to the meeting preview.
Are the trial results available in the source report?
No. The Nov. 6 report previews presentations scheduled for Saturday, Nov. 7, but does not provide trial outcomes or safety findings.
Why were these studies designed?
The report says the studies address evidence gaps because stroke survivors and people with type 2 diabetes were excluded from SPRINT. They examine whether intensive control is relevant in those separate populations.
When and where is the AHA meeting?
The main scientific sessions are scheduled for Nov. 7–9, 2026, in Chicago, with expanded programming beginning Nov. 6. Selected sessions will be livestreamed.
Source: medpagetoday.com
